shares in this article
As part of the phase III Himalaya study, the immunotherapy Imfinzi in combination with tremelimumab antibodies showed an unprecedented survival rate in liver cancer patients, as the British-Swedish pharmaceutical company announced. After a single dose of tremelimumab in combination with Imfinzi, 31 percent of treated patients are still alive after three years.
No increase in severe liver toxicity was associated with the combination. No risk of bleeding was observed either.
In addition, AstraZeneca announced that Imfinzi plus chemotherapy reduced the risk of death from advanced cholangiocarcinoma in first-line therapy by 20 percent compared to chemotherapy alone.
“The positive results of the Phase III Topaz-1 study demonstrated that AstraZeneca’s Imfinzi in combination with standard chemotherapy provided a statistically significant and clinically meaningful improvement in overall survival and progression-free survival compared to chemotherapy alone as a first-line treatment for patients with advanced bile duct cancer,” according to the company.
Imfinzi is approved for the treatment of advanced inoperable lung cancer.
AstraZeneca shares are currently up 0.19 percent in London at £87.44.
LONDON (Dow Jones)
More news about AstraZeneca PLC
Image Credits: Michael Vi / Shutterstock.com, Oli Scarff/Getty Images